Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04000087 · ClinicalTrials.gov registry record · NA

ECG AI-Guided Screening for Low Ejection Fraction

A NA study of Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction (Disorder), sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
358
Enrollment target
1
Study location

NCT04000087: Completed NA study of Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction (Disorder), sponsored by Mayo Clinic.

NCT04000087 is a NA study of Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction (Disorder) that has completed, run by Mayo Clinic. The registered enrollment target is 358 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04000087, a NA study of Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction (Disorder), has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
358 participants
Enrollment target
1
Study location

Study Summary

This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.

Primary Outcome

Ejection fraction obtained by echocardiography.

Interventions

  • OTHER AI-enabled ECG-based Screening Tool

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 358 participants
Start Date 2019-06-26
Est. Completion 2020-11-01
Phase NA
Mayo Clinic

2,844 total trials

What the finished NCT04000087 record still lists

NCT04000087 is an interventional study that assigns participants to a tested intervention. The registered 358 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (83% lower).

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which AI-enabled ECG-based Screening Tool is the first listed.

NCT04000087 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT04000087 about?

NCT04000087 is a clinical study titled "ECG AI-Guided Screening for Low Ejection Fraction". This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.

What is the current status of trial NCT04000087?

This trial is currently completed. It is a NA study. The enrollment target is 358 participants. The study started on 2019-06-26. Estimated completion is 2020-11-01.

What conditions does trial NCT04000087 study?

This clinical trial studies the following conditions: Heart Failure, Asymptomatic Left Ventricular Systolic Dysfunction (Disorder).

What interventions are being tested in trial NCT04000087?

The interventions under investigation include: AI-enabled ECG-based Screening Tool (OTHER).

Who is sponsoring clinical trial NCT04000087?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04000087 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04000087's enrollment target sits among peer trials

358 126th of 397 higher than 272 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04373317 · 358 participants · Phase 4

    Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

  • NCT05684965 · 358 participants · Phase 1

    XTX301 in Patients With Advanced Solid Tumors

  • NCT05824975 · 358 participants · Phase 1

    A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

  • NCT06480227 · 358 participants · NA

    Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04000087, the US trial registry maintained by the National Library of Medicine. NCT04000087 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.